Neuronetics Inc. Common Stock (STIM)
Stock · NASDAQ · Health Care
$1.89as of 10/16/2026
Price chart
Active signals
STIM Signal Track Record
How signals performed across all stocks →What STIM's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 45 | 0.0% | 49% | September 8, 2026 |
| Bollinger Band Breakout | 28 | +2.8% | 61% | August 4, 2026 |
| Bollinger Band Breakdown | 20 | -12.4% | 25% | September 28, 2026 |
| 200-Day Moving Average TouchActive now | 5 | -9.4% | 40% | August 29, 2025 |
| Any 20-session window (baseline) | -2.4% | 47% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About STIM
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength m…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 658
- Website
- neurostar.com/neuronetics/
Fundamentals
- 1-day range
- $1.85$1.97
- Market cap
- $156.57M
- P/E (trailing)
- —
- P/E (forward)
- -5.54
- EPS (trailing)
- $-0.44
- Dividend yield
- —
- Beta
- 1.32
- Avg. volume
- 1.83M
How Neuronetics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 17, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
Neuronetics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- STIMNeuronetics Inc. Common Stock$1.88▼ 3.33%Market cap $156.57MP/E —$0.8$3.44
- CVRXCVRx Inc. Common Stock$1.3▼ 6.47%Market cap $157.62MP/E —$1.28$11.3
- KRMDKORU Medical Systems Inc. Common Stock (DE)$3▼ 0.99%Market cap $163.52MP/E —$2.86$6.61
- RCELAvita Medical Inc. Common Stock$13.04▼ 2.76%Market cap $146.19MP/E —$3.22$13.73
- APYXApyx Medical Corporation Common Stock$2.55▼ 0.39%Market cap $174.35MP/E —$2.32$5.08
- MBOTMicrobot Medical Inc. Common Stock$0.95▲ 0.00%Market cap $120.90MP/E —$0.99$3.04
- LUCDLucid Diagnostics Inc. Common Stock$0.478▼ 8.08%Market cap $193.54MP/E —$0.5$1.63
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| STIM Neuronetics Inc. Common Stock | $156.57M | — | $1.88 | ▼ 3.33% | $0.8$3.44 |
| CVRX CVRx Inc. Common Stock | $157.62M | — | $1.3 | ▼ 6.47% | $1.28$11.3 |
| KRMD KORU Medical Systems Inc. Common Stock (DE) | $163.52M | — | $3 | ▼ 0.99% | $2.86$6.61 |
| RCEL Avita Medical Inc. Common Stock | $146.19M | — | $13.04 | ▼ 2.76% | $3.22$13.73 |
| APYX Apyx Medical Corporation Common Stock | $174.35M | — | $2.55 | ▼ 0.39% | $2.32$5.08 |
| MBOT Microbot Medical Inc. Common Stock | $120.90M | — | $0.95 | ▲ 0.00% | $0.99$3.04 |
| LUCD Lucid Diagnostics Inc. Common Stock | $193.54M | — | $0.478 | ▼ 8.08% | $0.5$1.63 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- BTIG Reiterates Buy on Neuronetics, Maintains $6 Price TargetBenzinga · 9/17/2026
- B. Riley Securities Initiates Coverage On Neuronetics with Buy Rating, Announces Price Target of $5Benzinga · 9/11/2026
Insider Activity
Insider Actions →- Jorey Chernett · August 14, 2026 · Buy14.0K @ $3.16
- Jorey Chernett · August 13, 2026 · Sale100 @ $3.21
- Nir Naor · July 23, 2026 · Grant500.0K
- Jorey Chernett · July 14, 2026 · Buy35.0K @ $1.78
- Avinash Amin · June 15, 2026 · J4.6K
- Avinash Amin · June 15, 2026 · J34.9K
- Avinash Amin · June 15, 2026 · J2.9K
- Madryn Health Partners II, LP · June 15, 2026 · J4.6K
- Madryn Health Partners II, LP · June 15, 2026 · J34.9K
- Madryn Health Partners II, LP · June 15, 2026 · J2.9K
- Madryn Health Partners II, LP · May 28, 2026 · J24.7K
- Madryn Health Partners II, LP · May 28, 2026 · J2.1K
- Avinash Amin · May 28, 2026 · Grant30.0K
- Sasha Cucuz · May 28, 2026 · Grant30.0K
- Megan Rosengarten · May 28, 2026 · Grant30.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 41.20M
- Total value held
- $59.52M
- Institutional holders
- 94
- Unknown18.48M
- Unknown2.87M
- Unknown2.74M
- Unknown2.32M
- Unknown2.05M
- Unknown1.77M
- Unknown1.49M
- Unknown1.00M
- Unknown959.0K
- Unknown842.5K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
STIM shifts focus from devices to psychedelic infrastructure
Neuronetics announced it is moving away from solely manufacturing its TMS device and is building a platform to support psychedelic therapies. The change aims to broaden the company's role in the emerging mental-health market. The stock is currently trading near its $1.19 support level and has an RSI of 25.4, indicating a low momentum environment.
STIM shifts focus from devices to psychedelic infrastructure. Neuronetics announced it is moving away from solely manufacturing its TMS device and is building a platform to support psychedelic therapies. The change aims to broaden the company's role in the emerging mental-health market. The stock is currently trading near its $1.19 support level and has an RSI of 25.4, indicating a low momentum environment.